Literature DB >> 8535213

Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry.

M Krogh-Jensen1, F D'Amore, M K Jensen, B E Christensen, K Thorling, M Pedersen, P Johansen, A M Boesen, E Andersen.   

Abstract

It has been claimed that Primary Central Nervous System Lymphomas (PCNSL), a rare neoplasm accounting for only a small fraction of malignant brain tumors and extranodal non-Hodgkin lymphomas (NHL), occur with increasing frequency in immunologically normal as well as in immunocompromised individuals. In an attempt to characterize the clinicopathological features, outcome and prognostic factors of PCNSL we here report our experience in a large unselected series of patients from a well-defined region. In addition, we present data on trends in incidence of PCNSL and primary malignant brain tumors in a well-defined geographical area. In a Danish population-based NHL registry (LYFO) representing a population of 2.7 million all new cases of NHL were registered during the approximate 11-year period from 1st January 1983 to 31st May 1994. Incidence data of primary malignant tumors of the brain and central nervous system in western Denmark for the period 1971-1990 have been obtained from the Danish Cancer Registry. During the approximate 11-year period 3124 new cases of NHL were registered. Of these, 1152 (37%) were extranodal and 48 were non-AIDS related PCNSL accounting for 4.2% of extranodal NHL and 1.5% of all NHL, respectively. The average annual incidence rate of non-AIDS related PCNSL during the period was 1.56 cases per million population (age range: 15-85 yrs, median: 62 yrs, M/F ratio: 1). In a 23-year period there was no trend towards an increasing incidence of non-AIDS related PCNSL in a well-defined population. PCNSL accounted for 1.7% of all primary malignant brain tumors. Incidence of primary malignant brain tumors was stable, except for age ranges over 70 years. However, diagnostic artifacts might be responsible for this apparent increase. Histologically, 85% were high grade. Using the Kiel classification centroblastic diffuse (60%) and immunoblastic lymphoma (13%) were the most common subtypes. Forty-three patients had B-cell lymphoma and no T-cell lymphoma was detected. Forty-seven cases were diagnosed pre mortem. Treatment included surgical resection (26 patients), whole brain irradiation (WBRT) (43 patients) and chemotherapy (28 patients). Median survival for those receiving either WBRT or WBRT and chemotherapy was 8 months and 20 months, respectively (p = 0.78). Overall survival was 53%, 38% and 26% at 1, 2 and 5 years. Cox-regression analysis identified only one factor having independent impact on survival in PCNSL: performances score > or = 2 (p < 0.001, RR = 5.8).

Entities:  

Mesh:

Year:  1995        PMID: 8535213     DOI: 10.3109/10428199509107892

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  13 in total

1.  Incidence and survival of primary central nervous system lymphoma (PCNSL): results from the Girona cancer registry (1994-2013).

Authors:  R Fuentes-Raspall; M Solans; C Auñon-Sanz; M Saez; R Marcos-Gragera
Journal:  Clin Transl Oncol       Date:  2018-05-23       Impact factor: 3.405

2.  Primary central nervous system non-Hodgkin lymphoma in childhood presenting as bilateral optic neuritis.

Authors:  Aurora Medina-Sanson; Fernado Chico-Ponce de León; María de Lourdes Cabrera-Muñoz; Sergio Gallegos-Castorena; Raul Caltenco-Serrano; Eduardo Barragán-Pérez
Journal:  Childs Nerv Syst       Date:  2006-04-06       Impact factor: 1.475

3.  Primary central nervous system lymphoma--a hospital based study of incidence and clinicopathological features from India (1980-2003).

Authors:  Chitra Sarkar; Mehar Chand Sharma; Prabal Deb; Rajbir Singh; Vani Santosh; S K Shankar
Journal:  J Neurooncol       Date:  2005-01       Impact factor: 4.130

4.  Diagnosis, treatment, and outcome of primary CNS lymphoma-a single-center experience.

Authors:  Joakim Wismann; Rune Hørlykke Sommer-Sørensen; Mikkel Seremet Kofoed; Bo Halle; Christian Bonde Pedersen; Mette Katrine Schulz; Mads Hjortdal Grønhøj; Thomas Stauffer Larsen; Michael Boe Møller; Frantz Rom Poulsen
Journal:  Acta Neurochir (Wien)       Date:  2022-03-07       Impact factor: 2.216

5.  The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings?

Authors:  Luís Alberto de Pádua Covas Lage; Vinícius Araújo Soares; Thales Dalessandro Meneguin; Hebert Fabrício Culler; Cadiele Oliana Reichert; Mayara D'Auria Jacomassi; Diego Gomes Cândido Reis; Maria Cláudia Nogueira Zerbini; Renata de Oliveira Costa; Vanderson Rocha; Juliana Pereira
Journal:  Radiat Oncol       Date:  2022-10-22       Impact factor: 4.309

Review 6.  Primary central nervous system lymphoma.

Authors:  Igor T Gavrilovic; Lauren E Abrey
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

7.  Differential diagnosis of a vanishing brain space occupying lesion in a child.

Authors:  Sherifa A Hamed; Mohamad A Mekkawy; Hosam Abozaid
Journal:  World J Clin Cases       Date:  2015-11-16       Impact factor: 1.337

8.  Age, gender, and racial differences in incidence and survival in primary CNS lymphoma.

Authors:  J L Villano; M Koshy; H Shaikh; T A Dolecek; B J McCarthy
Journal:  Br J Cancer       Date:  2011-09-13       Impact factor: 7.640

9.  Spontaneous regression of congenital brain tumors: a report of two cases.

Authors:  Ghazaleh Kheiri; Zohreh Habibi; Farideh Nejat
Journal:  Childs Nerv Syst       Date:  2021-05-01       Impact factor: 1.475

10.  Clinicopathological Features and Outcomes in Primary Central Nervous System Lymphoma: A 10-year Experience.

Authors:  Chaitanya Krishna Puligundla; Stalin Bala; Ashok Kumar Karnam; Sadashivudu Gundeti; Tara Roshni Paul; Megha S Uppin; Lakshmi Srinivas Maddali
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.